Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.37 |
| ▸ | IL2 | P60568 | 4/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 3/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096594 | 0.88 | STIM1 (0.44) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL11940274 | 0.87 | IL2 (0.41) | MEN1KMT2ARORCCRACR2AIL2 | |
| SCHEMBL3103841 | 0.87 | MEN1 (0.40) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL646344 | 0.86 | RXRA (0.44) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL647154 | 0.85 | RAB9A (0.43) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL3097975 | 0.85 | IL2 (0.39) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL10124778 | 0.85 | RORC (0.35) | MEN1KMT2ARORCHCRTR1CRACR2A | |
| SCHEMBL647102 | 0.84 | IL2 (0.41) | MEN1KMT2ARORCCRACR2AIL2 | |
| SCHEMBL3111761 | 0.84 | LMNA (0.46) | MEN1KMT2ARORCIL2 | |
| SCHEMBL13099813 | 0.83 | RORC (0.37) | MEN1KMT2ARORCCRACR2AIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | IL5, CXCR5, NLRP3 | MEN1 4248/4885KMT2A 3225/4885RORC 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.